NCT04144517View on ClinicalTrials.gov

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

October 8, 2021

Study Completion Date

January 7, 2022

Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
DRUG

Nemvaleukin Alfa

Nemvaleukin alfa IV infusion.

DRUG

Pembrolizumab

Pembrolizumab IV infusion.

Trial Locations (7)

10016

Mural Oncology Investigational Site, New York

10029

Mural Oncology Investigational Site, New York

30308

Mural Oncology Investigational Site, Atlanta

33136

Mural Oncology Investigational Site, Miami

44195

Mural Oncology Investigational Site, Cleveland

55455

Mural Oncology Investigational Site, Minneapolis

78712

Mural Oncology Investigational Site, Austin

Sponsors
All Listed Sponsors
collaborator

Immune Oncology Network (ION)

UNKNOWN

lead

Mural Oncology, Inc

INDUSTRY

NCT04144517 - A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer | Biotech Hunter | Biotech Hunter